Cáncer de mama

  1. Álvarez Fernández, J. 1
  2. Palacios Ozores, P. 1
  3. Cebey López, V. 1
  4. Cortegoso Mosquera, A. 1
  5. López López, R. 1
  1. 1 Servicio de Oncología Médica y Grupo de Oncología Médica Traslacional, Hospital Clínico Universitario e Instituto de Investigación Sanitaria-CIBERONC, Santiago de Compostela, La Coruña, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Título do exemplar: Enfermedades oncológicas (IV)Melanoma, cáncer de mama y tumores ginecológicos

Serie: 13

Número: 27

Páxinas: 1506-1517

Tipo: Artigo

DOI: 10.1016/J.MED.2021.03.002 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Obxectivos de Desenvolvemento Sustentable

Resumo

El cáncer de mama representa la principal causa de muerte por tumores malignos en mujeres. Se considera una entidad multifactorial, con una clara vinculación con los factores hormonales y reproductivos de las pacientes. La presentación clínica más habitual es la existencia de una masa indolora a nivel local. Su diagnóstico se basa en la tríada de valoración clínica, prueba de imagen y biopsia, destacando la mamografía como prueba esencial del cribado poblacional. Su pronóstico se relaciona con el subtipo biológico y el estadio tumoral al diagnóstico. Los objetivos y la modalidad de tratamiento varían en función del estadio tumoral. En el tratamiento de estadios precoces, el cual persigue una intención curativa, además de los tratamientos locales con cirugía y radioterapia, destaca el sistémico adyuvante o neoadyuvante, con quimioterapia, hormonoterapia, tratamiento biológico y/o combinaciones de estos. En presencia de enfermedad metastásica, el objetivo del mismo es paliativo. En esta situación, a las terapias clásicas con quimioterapia y hormonoterapia, se les ha asociado en los últimos años otras nuevas terapias.

Referencias bibliográficas

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2018;68:394-424.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics. Cancer J Clin. 2020; 70:7-30.
  • Lauby Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer viewpoint of the iARC Working Group. New Engl J Medicine. 2016;375:794-8.
  • Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant metaanalysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141-51.
  • Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387-97.
  • Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years. New Engl J Medicine. 2017;377:1836-46.
  • Corben AD, Brogi E. Ductal carcinoma in situ and other intraductal lesions: pathology, immunohistochemistry and molecular alterations. En: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. 5a ed. Philadelphia: Wolters Kluwer Health; 2014. p. 309-23.
  • King TA, Resi Filho JS. Lobular carcinoma in situ: biology and management. En: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. 5a ed. Philadelphia: Wolters Kluwer Health; 2014. p. 324-36.
  • Dillon DA, Guidi AJ. Pathology of invasive breast cancer. En: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. 5a ed. Philadelphia: Wolters Kluwer Health; 2014. p. 381-410.
  • Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
  • Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez Les cure A, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncol. 2015;20:474-82.
  • Prat A, Pascual T, Adamo B. Intrinsic molecular subtypes of HER2+ breast cancer. Oncotarget. 2017;8:73362-3.
  • Perou CM. Molecular stratification of triple negative breast cancers. Oncol. 2010;15:39-48.
  • Koo MM, Wagner C von, Abel GA, McPhail S, Rubin GP, Lyratzopoulos G. Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national au-dit of cancer diagnosis. Cancer Epidemiol. 2017;48:140-6.
  • Sickles EA, D'Orsi CJ, Bassett LW, et al. ACR BI-RADS® Mammography. En: Bell DJ, Weerakkody Y, eds. Atlas, Breast imaging reporting and data system (BI-RADS). American College of Radiology; 2013.
  • Hindle WH, Davis L, Wright D. Clinical value of mammography for symptomatic women 35 years of age and younger. Am J Obstet Gynecol. 1999;180:1484-90.
  • Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Whashington MK, et al. AJCC Cancer Staging Manual. 8ª ed. 2017.
  • Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312.
  • Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31:3997-4013.
  • Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty year follow up of a randomized study comparing breast conserving surgery with radical mastectomy for early breast cancer. New Engl J Medicine. 2002;347:1227-32.
  • Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty year follow up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Medicine. 2002;347:1233-41.
  • Schnitt SJ, Moran MS, Houssami N, Morrow M. The Society of Surgical Oncology American Society for Radiation Oncology consensus guideline on margins for breast conserving surgery with whole breast irradiation in stages I and II invasive breast cancer: perspectives for pathologists. Arch Pathol Lab Med. 2014;139:575-7.
  • Morrow M, Zee KJV, Solin LJ, Houssami N, Chavez MacGregor M, Harris JR, et al. Society of Surgical Oncology American Society for Radiation Oncology American Society of Clinical Oncology Consensus Guideline on margins for breast conserving surgery with whole breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016;34:4040-6.
  • Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10 year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Jama. 2017;318:918-26.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast conserving surgery on 10 year recurrence and 15 year breast cancer death: meta analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707-16.
  • EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10 year recurrence and 20 year breast cancer mortality: meta analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383: 2127-35.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005365:1687-717.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient level meta analysis of the randomised trials. Lancet. 2015;386: 1341-52.
  • Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018 Aug 1;29(8):1634-57.
  • Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first line treatment of oestrogen receptor positive, HER2 negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35.
  • Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first line therapy for hr positive, advanced breast cancer. New Engl J Medicine. 2016;375:1738-48.
  • Goetz MP, Toi M, Campone M, Sohn J, Paluch Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-46.
  • Smith TJ. Breast Cancer Surveillance Guidelines. J Oncol Pract. 2013; 9:65-7.
Fonte de datos: Dialnet